TENX

Tenax Therapeutics, Inc.

TENX · CIK 34956 · Annual (10-K) · Last 8 years

Financial Trends

Revenue$0M
20172024
Net Income−$18M
20172024
Operating CF−$15M
20172024
Free Cash Flow
20172024

Income Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕FY 2017↕
Revenue$0.0B———————
Cost of Revenue————————
Gross Profit————————
R&D Expense$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
SG&A Expense———$0.0B$0.0B$0.0B$0.0B$0.0B
Operating Income$-0.0B$0.0B$-0.0B$0.0B$-0.0B$-0.0B$-0.0B$-0.0B
Net Income$-0.0B$0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B
EPS (Basic)$-1.15———————
EPS (Diluted)$-1.15———————

Balance Sheet

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕FY 2017↕
Total Assets$0.1B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Current Assets$0.1B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Cash & Equivalents$0.1B—$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Total Liabilities$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Current Liabilities$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Stockholders' Equity$0.1B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B

Cash Flow Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕FY 2017↕
Operating Cash Flow$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B
Investing Cash Flow$0.0B$0.0B$-0.0B$0.0B$0.0B$-0.0B$0.0B$0.0B
Capital Expenditures——$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.1B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B—
← Companies